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Summary
Atypical hemolytic uremic syndrome (aHUS) is caused by several susceptibility genes. A registry including analyses of
susceptibility genes, familial occurrence and genotype-phenotype correlation should provide classification insights.
Registry data of 187 unrelated index patients included age at onset, gender, family history, relapse of aHUS and potentially
triggering conditions. Mutation analyses were performed in the genes CFH, CD46 and CFI and in the six potential
susceptibility genes, FHR1 to FHR5 and C4BP.
Germline mutations were identified in 17% of the index cases; 12% in CFH, 3% in CD46 and 2% in CFI . Twenty-nine
patients had heterozygous mutations and one each had a homozygous and compound heterozygous mutation. Mutations
were not found in the genes FHR1-5 and C4BP. In 40% of the patients with familial HUS a mutation was found.
Penetrance by age 45 was 50% among carriers of any mutation including results of relatives of mutation-positive index
cases. The only risk factor for a mutation was family history of HUS (p = 0.02).
Penetrance of aHUS in carriers of mutations is not complete. Occurrence of homo- and heterozygous mutations in the
same gene suggests that the number of necessary DNA variants remains unclear. Among clinical information only familial
occurrence predicts a mutation.
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Introduction
Hemolytic uremic syndrome (HUS) is characterised by non-
immunogenic hemolytic anemia, low platelet count and
deterioration of renal function. Laboratory findings include
decreased hemoglobin, erythrocytes, platelets, haptoglobin,
fragmentocytes in the blood smear, and negative Coombs
test. Thrombotic microangiopathy is the histomorphologic
correlate. Atypical hemolytic uremic syndrome (aHUS), the
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counterpart of classic HUS represents most cases of HUS in
adulthood. In contrast to typical HUS which is induced by
infections of bacteria producing Shiga like toxins, mostly by
enterohaemorrhagic escherichia coli strain O157:H7, aHUS
is not associated with diarrhoea (Kaplan et al., 1998; George,
2006). The clinical classification of aHUS is based on as-
sociated conditions, mainly with exposure to certain drugs
like ovulation inhibitors or platelet aggregation inhibitors,
with various disorders like acute infections of the respira-
tory and gastrointestinal tracts and changes of life cycle like
pregnancy (George, 2006). In contrast to classic HUS, plasma
exchange and substitution by fresh frozen plasma is an es-
tablished therapy for aHUS and has considerably ameliorated
the poor spontaneous prognosis of aHUS (Rock et al., 1991).
However, patients with aHUS and endstage renal failure have
a further burden of recurrence after kidney transplantation
(25-60%) (Agarwal et al., 1995; Artz et al., 2003) and trans-
plant failure after recurrence of HUS (90%) (Conlon et al.,
1996; Miller et al., 1997; Lahlou et al., 2000; Kavanagh
et al., 2008).
New insights into the molecular genetics and the patho-
physiological background of aHUS have been provided in
recent years. Genetic linkage analyses of families with HUS
gave evidence for a susceptibility gene on chromosome 1q32
which was subsequently identified as the gene encoding fac-
tor H (CFH) (Warwicker et al., 1998). Subsequently, another
component of the complement cascade, the CD46 gene en-
coding the membrane cofactor protein (MCP) has also been
identified as a susceptibility gene for aHUS (Noris et al.,
2003; Richards et al., 2003). Finally, the family of susceptibil-
ity genes for HUS has been extended to the gene encoding
the complement factor I, CFI (Fremeaux-Bacchi et al., 2004;
Kavanagh et al., 2005; Caprioli et al., 2006). Interestingly at
the same chromosomal locus 1q32 a clustering of genes en-
coding proteins involved in the complement system has been
found. These genes form the RCA (regulators of comple-
ment activation) cluster and comprise among others the genes
FHR-1, FHR-2, FHR-3, FHR-4, FHR-5, CFH, CD46 and
C4BP (Rey-Campos et al., 1988).
For clinicians, primarily nephrologists, the frequency of
carriers of germline mutations in susceptibility genes among
patients with aHUS and potential correlations with clini-
cal features are of great interest. We have addressed these
questions in regard to the aHUS patients of our registry for
the genes CFH, CD46 and CFI . Furthermore, in order to
identify other susceptibility genes, we screened registrants for
germlinemutations in the genes FHR 1-5 andC4BP alpha and
beta.
Three susceptibility genes which were recently described
as being associated with HUS, C3, factor B (FB) and throm-
bomodulin, were not considered for molecular analysis in this
study (Goicoechea de Jorge et al., 2007; Fremeaux-Bacchi
et al., 2008; Delvaeye et al., 2009).
Materials and Methods
The Registry of Patients with aHUS
The registry for aHUS based in Freiburg, Germany was es-
tablished in 1998 for German speaking countries including
Germany, Switzerland, Austria and northeast Italy (Alto Adige)
(Neumann et al., 2003). Initially dedicated to adults, the registry
was later extended to patients in childhood and adolescence.
Index cases with aHUS who provided EDTA anticoagulated
blood, demographic and clinical data were included. Among
subjects with a positive family history for HUS, the affected
relatives were asked for the same items. Patient data included
haemoglobin, platelet count, serum creatinine, lactate dehydro-
genase and haptoglobin as well as fragmentocytes in the blood
smear and negative Coombs test in the acute episode. Clin-
ical events preceding the acute HUS episode were recorded;
these included acute infections, cancer, autoimmune diseases,
intake of drugs such as platelet aggregation inhibitors, ovula-
tion inhibitors, chemotherapeutics or immunosuppressive med-
ication or special diet components like quinine, and life cycle
changes such as pregnancy or postpartum period. In addition
we recorded renal biopsy findings in the acute phase of HUS
and relapse episodes after the acute phase. We re-evaluated the
registrants for a previous infection by the major shiga-like toxin-
producing bacteria E. coli strain O157:H7 and measured serum
C3 and factor H. We excluded patients with positive E. coli
serology, patients without impairment of renal function, pa-
tients with neurological deficits which were regarded as signs
for TTP and patients who developed HUS only after kidney
transplantation.
Special attention was put on patients thought to be at high risk
of developing aHUS. This group consisted of patients with famil-
ial HUS, those with relapsing HUS after remission documented
by renal function, platelet count and haptoglobin after treatment
by plasma membrane separation and substitution of fresh frozen
plasma, and patients with aHUS in young age defined as 40 years
or younger. Finally, we contacted all patients initially and during
follow up for outcome and recorded, in particular, occurrence
of endstage renal failure.
Mutation Screening in Susceptibility Genes
and Candidate Genes
All patients were tested for susceptibility genes CFH, CFI and
CD46 (Kavanagh et al., 2008). For CFH analyses until 2004 we
used single strand confirmation polymorphism (SSCP) and after
this time denaturing high performance liquid chromatography
was used (DHPLC, WAVE system, model 3500 HT, Transge-
nomic, Glasgow, United Kingdom). The genes CD46 and CFI
were exclusively analyzed by DHPLC. In addition we analyzed
the potential candidate genes FHR-1, FHR-2, FHR-3, FHR-4,
FHR-5 andC4BP byDHPLC.Direct sequencing was performed
if DHPLC showed abnormal chromatographies or SSCP aber-
rant bands.
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Quality Check for Sensitivity and Specificity
of SSCP and DHPLC
Direct sequencing is the gold standard for intraexonic muta-
tion analysis whereas generic sensitivity of 86-100% with SSCP
and 93-100% with DHPLC are inferior (Xiao & Oefner, 2001;
Bettinaglio et al., 2002), but more cost effective. Regarding SSCP,
we chose 40 index cases in which SSCP showed normal results
for CFH. Regarding DHPLC, we chose 13 index cases in which
DHPLC showed normal results for CFH and 40 index cases
in which DHPLC showed normal results for CD46 and CFI.
Direct sequencing was performed to confirm results of both
methods in 40 (SSCP) and 13 (DHPLC) index cases for the gene
CFH, and in 40 index cases (DHPLC) for the genes CD46 and
CFI . Results showed normal findings in all genes. Furthermore,
we compared sensitivity of SSCP versus DHPLC exclusively in
thoseCFH exons in which SSCP showed a DNA variant. Again,
DHPLC was abnormal in all these SSCP samples. In summary,
sensitivity of SSCP and DHPLC in CFH analyses is identical and
100% in this quality check. Therefore, we did not re-investigate
other index cases which were analyzed by SSCP.
Interpretation of DNA Variants
DNA variants creating stop codons or truncation of the putative
protein due to splice site alteration as well as intra-exonic dele-
tions or insertions were regarded as pathogenetically relevant,
i.e. mutations. In contrast, this is not self-evident for missense
variants which were, therefore, tested in 100 healthy blood-
donor controls (200 chromosomes). Missense variants were re-
garded as mutations, if they were not observed in the controls.
For each missense mutation we checked the affected codons for
evolutionary conservation among species using the EPO Multi-
ple Alignment Analysis provided by ENSEMBL Browser (Flicek
et al., 2008). Furthermore, we conducted in silico analysis based
on sequence similarity analyses, the physical properties of amino
acids, and the structure and function of human proteins using the
SIFT predictor Software (Ng & Henikoff, 2006). For compound
heterozygous and homozygous missense mutations an additional
1000 controls were screened.
Genetic Testing of Family Members
Relatives of patients with identified mutations were offered mu-
tation screening. Registered clinical data of relatives included the
same items as for the index cases.
Statistical Analysis
We tested the hypothesis of an association between the clin-
ical/demographic data and presence of any mutation in pa-
tients in which all three genes (CFH, CD46 and CFI) were
tested. Further, we assessed the association between the clini-
cal/demographic data and the presence of a mutation for all the
patients studied for each gene separately. These analyses were
done using a two-sided Fisher’s exact test. Age-dependent pen-
etrance was estimated using the Kaplan-Meier method.
This study was approved by the Ethical Committee of the
Freiburg University Medical Center. All patients gave written
informed consent.
Results
The analysis included 187 unrelated index cases with aHUS,
112 females and 75 males, age 3 months to 78 years (mean
30 years) at diagnosis (±0.08) of the disease. Of the 187 cases,
31 probands were mutation positive. These 31 index patients
carried a mutation in one of the genes, CFH, CD46 or CFI .
Twenty-two index cases (12%) showed CFH mutations, 6
index cases (3%) showed CD46 mutations, and 3 index cases
(2%) cases were carriers of a CFI mutation.
Further, we included in the analyses 48 relatives from 24
of the 31 mutation positive index cases, demonstrating the
mutations in 23 of these 48. In five of these 24 index cases
familial HUS was present. Mutations could be demonstrated
in eight relatives of four families (Fig. 1, panel A).
DNA Variants of the CFH Gene
There were 33 total CFH DNA variants, which included 22
differentCFH mutations and 11 polymorphisms (Tables 1 and
2). The mutations comprised 16 missense, one splice site and
two stop codon mutations, and two small deletions of three
and four nucleotides respectively. All mutations were located
in exons 14-23 of the CFH gene. Three of the mutations
have not yet been reported. The already reportedCFH c.3701
C>T mutation was found in one case together with the CFH
c.3135 A>T mutation. In another case, the CFH c.3701
C>T mutation was the only mutation. The CFH c.2770
T>A (P.Y899X) mutation was only found in one case from
consanguineous parents and was homozygous in the index
case. Twenty-two of 187 patients (12%) hadCFH mutations.
DNA Variants of the CD46 Gene
A total of seven different intra-exonic and splice site DNA
variants have been found in theCD46 gene. These comprised
five mutations and two polymorphisms (Tables 1 and 2).
The mutations were one stop codon, one splice site and two
missense mutations, and one small deletion of one nucleotide.
One of the mutations has not yet been reported. Six of 187
patients (3%) had CD46 mutations; one mutation was seen
in two index cases.
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Figure 1 Pedigrees of mutation-positive index cases with familial HUS (A: four families) and without familial HUS (B: eight
families).
DNA Variants of the CFI Gene
A total of five different intra-exonic and splice site variants
were found in the CFI gene, three mutations and two poly-
morphisms (Tables 1 and 2). The mutations comprised three
missense mutations. Two mutations have not yet been re-
ported. Three of 187 (2%) cases were carriers of a CFI mu-
tation.
DNA Variants of the Genes FHR 1-5 and C4BP
No pathogenic relevant variants were found in these six genes.
Identified polymorphisms are listed in Table 2.
Familial HUS
A total of 15 index cases had a family history of HUS; mu-
tations were detected in six (40%) of these. In five muta-
tion positive cases blood DNA was available from 11 relatives
including seven parents. In these relatives, eight additional
mutation carriers were found (Fig. 1, panel A).
Relatives of Patients with Mutations
In 25 index cases with a mutation, there was no family history
of HUS. From 19/25 of these mutation carriers a total of 37
relatives were available for genetic testing. Both parents were
available for genetic testing from 11 index cases. For six cases
the mutation was found in one parent and for two cases a
mutation was found in both parents (Fig. 1, panel B), whereas
in three cases de novo mutations occurred, since none of the
parents were carriers; haplotype analysis confirmed paternity.
Re-interviews and investigations showed normal serum
creatinine levels and no evidence for HUS in these ten
newly recognized carriers. For the index case who showed a
compound heterozygous mutation, CFH c.3701 C>T and
c.3135 A>T, the first mutation was found in the mother,
the second in the father, neither of whom ever had HUS.
For the index case with the homozygous mutation, CFH
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Table 1 New and previously published mutations in the genes CFH, CD46 and CFI.
SCR Exon Nucleotide AA Mutationtype Previously described
CFH gene mutations
11 14 1963 T>G C630W Missense (Neumann et al., 2003)
12 15 2214 C>G S714X Nonsense (Neumann et al., 2003)
14 17 2576 G>T V835L Missense (Saunders et al., 2006)
14 17 2621 G>A E850K Missense (Neumann et al., 2003)
15 18 2770 T>A homoz. Y899X Nonsense (Caprioli et al., 2006)
16 19 3007 G>T W978C Missense (Neumann et al., 2003)
17 20 3135 A>T Y1021F Missense (Neumann et al., 2003)
17 20 3200 T>C C1043R Missense (Neumann et al., 2003)
18 21 3299 C>G Q1076E Missense (Richards et al., 2001; Neumann et al., 2003)
19 22 3474 T>G V1134G Missense (Neumann et al., 2003)
19 22 3478 G>C E1135D Missense New
19 22 3497 T>G Y1142D Missense (Neumann et al., 2003)
19 22 3542 T>C W1157R Missense (Neumann et al., 2003)
19 22 3566 + 1 G>A Splice-Defect (Neumann et al., 2003)
20 23 3619 G>T R1182S Missense New
20 23 3620 T>C W1183R Missense New
20 23 3645 C>T S1191L Missense (Richards et al., 2001; Heinen et al., 2006)
20 23 3701 C>T R1210C Missense (Caprioli et al., 2001; Sanchez-Corral et al., 2002)
20 23 3719  del ACA In-Frame Deletion Frameshift (Neumann et al., 2003)
20 23 3749 C>T P1226S Missense (Neumann et al., 2003)
20 23 3767 del AGAA X1232FfsX38 Frameshift (Neumann et al., 2003)
CD46 gene mutations
1 1 104 G>A C35Y Missense (Caprioli et al., 2006)
1 1 175 C>T R59X Nonsense (Caprioli et al., 2006)
1 1 286 + 2 T>G Splice-Defect (Fremeaux-Bacchi et al., 2006)
2 3 404 del G G135VfsX13 Frameshift New
3 4 565 T>G Y189D Missense (Fremeaux-Bacchi et al., 2006)
CFI gene mutations
4 485 G>A G162D Missense New
4 491 A>T D164V Missense New
5 772 G>A A258T Missense (Vyse et al., 1996)
c.2770 T>A, the mutation was present in both parents in
heterozygous form. From two index cases a sibling was avail-
able for testing who were both positive, but without a history
of HUS.
Penetrance of HUS in CFH, CD46, and CFI
Germline Mutation Carriers
Age-dependent HUS penetrance was estimated for all 54
subjects carrying a CFH, CD46, or CFI mutation (Fig. 2
Panel A). These data demonstrate an incomplete penetrance
of HUS in mutation carriers with a manifestation of HUS in
50% of the carriers by age 45. The data are more robust for
CFH, since 39 patients had mutations in this gene compared
to ten and five with mutations of the genes CD46, and CFI
respectively, but for all genes penetrance reached 50% in the
5th decade of life (Fig. 2 Panel B, C and D).
Genotype-Phenotype Correlations – Predictors
For Mutations in any Susceptibility Gene
Regarding conditions which predispose or potentially predis-
pose to aHUS (Table 3), a germline mutation was identified
in six of 15 index cases with familial HUS (p = 0.02). Con-
sidering the distribution of mutation positive cases through
different age intervals (Fig. 3), the proportion of mutation
positive cases was higher in patients at age ≤40 (28/143;
20%) in contrast to those who were older (4/44; 9%), a trend
toward statistical significance (p = 0.06). Relapsing HUS oc-
curred in 53 index cases of whom ten (19%) had a mutation
(p = 0.66).
Regarding conditions which potentially triggered the man-
ifestation of aHUS, 91 index cases had either concomitant
acute or chronic inflammatory diseases (43 cases), malignan-
cies (seven cases), pharmacological treatment with ovulatory
inhibitors (11 cases) or other drugs (12 cases), pregnancy or
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Table 2 CFH, CD46, CFI , FHR-1, FHR-5 and C4BP gene poly-
morphisms in patients of the Freiburg registry.
Occurrence
in Healthy
SCR Exon Nucleotide AA probands in %
CFH gene polymorphisms
1 80 C>G Intron
1 2 257 G>A V62I 2∗/3∗∗
5 7 994 C>A A307A
7 9 1277 C>T H402Y 49∗/36∗∗
8 11 1492 G>A A473A
11 14 2089 A>G Q672Q
15 18 2707 C>T H878H 2∗/0∗∗
16 19 2881 G>T E936D 18∗/2∗∗
16 19 2923 G>T Q950H 2∗/0∗∗
16 19 2881 + 2923 E936D+Q950H 2∗/0∗∗
18 21 3211 C>T T1046T
18 21 3221 A>T N1050Y 6∗/0∗∗
CD46 gene polymorphisms
2 3 417 A>G L139L 2∗/0∗∗
4 5 718 T>C S240P 3∗/1∗∗
CFI gene polymorphisms
6 782 G/A G261D 1∗/0∗∗
6 804 G>A G268G 3∗/0∗∗
FHR-1 gene polymorphisms
4 4 578 C>T H157Y 28∗/29∗∗
4 4 584 C>G L159V 28∗/29∗∗
4 4 632 G>C E175Q 28∗/29∗∗
4 4 697 A>G T196T 28∗/29∗∗
5 5 778 G>A P223P 14∗/11∗∗
FHR-5 gene polymorphisms
7 7 1067 G>A R356 25∗/0∗∗
C4BP-alpha gene polymorphisms
2 11 C>A P4Q 10∗/0∗∗
5 8 899 T>C I300T 51∗/56∗∗
C4BP-beta gene polymorphisms
3 4 462 C>T N154N 47∗/0∗∗
∗heterozygote/∗∗homozygote.
postpartum period (27 cases) prior to onset of HUS. Among
these 91 index cases, 16 (18%) had a mutation. The frequency
of mutations with concomitant diseases was 21% (9/43). One
mutation was found in one patient with malignancy. Sig-
nificant association was not found between the presence of
mutations and any of the specific triggering factors of HUS
(Table 3). No significant association was observed between
these conditions and germline mutations in the CFH, CD46
and CFI genes (Table 4).
Renal outcome information was available for 183/187 reg-
istrants including 30/31 mutation carriers. Endstage renal dis-
ease (ESRD) developed in 91 of 153 registrants without a
mutation and in 20 of 30 registrants with a mutation in CFH,
CD46 or CFI (p = 0.54). Regarding the different genes,
ESRD was observed in carriers of a CFH (n = 15), CD46
(n = 2) and CFI (n = 3) mutation (Tables 3 and 4).
Discussion
We present a study on 187 unrelated index patients with
aHUS screened for germline mutations in the genes CFH,
CD46 and CFI . A total of 31 index cases harbour a germline
mutation, 22 in the CFH gene, six in the CD46 gene and
three in the CFI gene. About one fifth (19%) of detected mu-
tations in this registry have not yet been described (Saunders
et al., 2006). The mutation detection rate is 17% and thus
somewhat lower compared to the reports of 22% – 51%
from the groups in Newcastle, Paris, Madrid and Bergamo
(Esparza-Gordillo et al., 2005; Fremeaux-Bacchi et al., 2005;
Caprioli et al., 2006; Fremeaux-Bacchi et al., 2006). The
detection rate in these groups might be biased through the
pre-selection of cases considered as “high risk for inheri-
tance”. These are cases with positive family history, relapsing
HUS and young age at diagnosis. Our results are based on
unselected registrants and are likely to represent the true de-
tection rate in patients with aHUS. Our data confirmed that
mutations in the genes CD46 and CFI are less frequent than
those in the CFH gene.
Recently, three additional susceptibility genes for aHUS
have been described (Goicoechea de Jorge et al., 2007;
Fremeaux-Bacchi et al., 2008; Delvaeye et al., 2009). The
genes factor B (FB) and C3 have been shown to be mu-
tated in two and 11 index cases respectively so far. These
genes were exclusively mutated in patients with aHUS and
decreased serum C3 levels. The third gene is the gene throm-
bomodulin (Delvaeye et al., 2009). We did not consider per-
forming mutation screening in these newly identified genes
since we focused our study on the genesCFH,CD46 andCFI
and also because of the high costs for a large cohort such as
ours.
Two cases in this series are particularly remarkable. One
patient showed the mutation CFH c.2770 T>A. This is a
stop codon mutation which predicts a truncated protein and
is seemingly doubtless pathogenic. In our index case, however,
this mutation is homozygous and inherited from both parents
who are heterozygous and without manifestation of HUS.
The second case shows two CFH mutations, c.3135 A>T
and c.3701 C>T, both of the missense type. According to the
results in both parents, who each were carriers of one muta-
tion respectively, this index case is compound heterozygous.
Of note, one of the two mutations, c.3701 C>T, was the
only mutation in another index case. In fact, similar cases are
reported in the literature (Caprioli et al., 2006; Fremeaux-
Bacchi et al., 2006). It remains unclear how to understand
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Figure 2 Penetrance of HUS in germline mutation carriers of the genes CFH, CD46, and CFI .
Table 3 Clinical phenotype and presence/absence of any mutation.
Mutation Mutation total p
Patients characteristics neg (156) pos (31)
Predisposing conditions
Age ≤40 115 28 143 0.06
Relapsing HUS 43 10 53 0.66
Family History for HUS 9 6 15 0.02
Potentially triggering conditions
Ovulation Inhibitors 7 4 11 0.09
Other Drugs 11 1 12 0.69
Pregnancy/Post Partum 24 3 27 0.58
Other Disorders 40 10 50 0.51
Outcome
ESRD 91 20 111 0.54
these findings which considerably weaken the concept that
a single germline mutation defines a disease predisposition
and encompasses this powerful condition. The dosage of re-
quired predisposing events thus became unclear. The current
understanding of pathogenesis of aHUS considers the muta-
tions themselves as one of the susceptibility factors but not
the entire cause of the disease. In the pathogenesis endothelial
insults due to infections, drugs, pregnancy or other events are
required for initiation of uncontrolled complement activation
leading to further damage to blood vessels and thrombotic
microangiopathy (Fang et al., 2008).
Notably, the variant CD46 c.718 T>C (corresponding to
RefSeq NM_172359.1), which was previously described as
a mutation by Richards et al. (2003) was also found in one
of our patients and in four controls. Three of the controls
were heterozygous and one was homozygous for this variant.
We then tested to determine whether the nucleotide is highly
conserved among different species, and whether the resulting
amino acid change is predicted to be deleterious, in order to
clarify the pathogenic role of these variants. The nucleotide
was conserved among species and the amino acid change
predicted to be tolerant. Taking the calculated result together
with the 4% incidence in our control samples, we classified
this variant as a polymorphism.
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Figure 3 Distribution of mutation-positive cases through different age intervals.
Table 4 Clinical phenotype and presence/absence of specific gene mutations.
CFH gene mutations CD46 gene mutations CFI gene mutations
neg (165) pos (22) p neg (181) pos (6) p neg (184) pos (3) p
Patients characteristics
Age ≤40 123 20 0.11 137 6 0.34 141 2 0.56
Relapsing HUS 48 5 0.62 49 4 0.06 52 1 >0.99
Family History for HUS 12 3 0.39 13 2 0.08 14 1 0.22
Potentially triggering conditions
Ovulation Inhibitors 8 3 0.13 10 1 0.31 11 0 >0.99
Other Drugs 12 0 0.37 12 0 >0.99 11 1 0.18
Pregnancy/Post Partum 25 2 0.75 27 0 0.60 26 1 0.38
Other Disorders 43 7 0.61 48 2 0.66 49 1 >0.99
Outcome
ESRD 96 15 0.35 109 2 0.21 108 3 0.28
Based on a total of 54 mutation carriers we estimated the
penetrance for HUS. Remarkably, none of the newly recog-
nized carriers had any evidence for an episode of HUS and
kidney function was normal. Consequently, the penetrance
was far from complete and reached only 50% by the age of
40-50 years for all carriers of any mutation in any of the three
genes as well as for carriers of one of the three genes separately
(Fig. 2 Panels A-D).
With an increase in the number of susceptibility genes in-
volved in the genetic predisposition for aHUS, it becomes
important to determine which subjects are at higher risk of
having a germline mutation and which gene should be ana-
lyzed. We focused this issue by using three potential mutation
predictors: familial HUS, relapsing HUS and young age at
onset (age of ≤40 years). Family history was the only risk
factor for the presence of an inherited disorder (p = 0.02).
Interestingly, 25 of the 31 (81%) mutation carriers did not
present with positive family history. Furthermore, it is of in-
terest that in nine of 15 cases (60%) with positive family
history the responsible gene was not identified in this study,
indicating that the inheritance pattern for aHUS is still not
completely clarified. Relapsing aHUS, seen in 54 of our in-
dex cases was not found to be associated with presence of an
inherited disorder (P = 0.66). However, considering the three
genes separately, an association toward significance could be
observed for relapsing HUS and CD46 germline mutations
(p = 0.06). The age of ≤40 years is a cut-off of potential in-
terest (p = 0.06) and needs to be confirmed by other studies.
Finally renal outcome with endstage renal disease was ob-
served in patients without mutations as well as in patients with
mutations in the susceptibility genes CFH, CD46 and CFI
and thus, endstage renal disease does not represent a predictor
for such mutations.
In summary, this large registry with 187 index cases of pa-
tients demonstrates germline mutations within one of three
susceptibility genes in 17% of patients with atypical HUS.
Twenty-three of 54 relatives were also mutation carriers but
without evidence for aHUS episodes, which lowers the pen-
etrance for the disease to 50% in the 5th decade of life. The
only risk factor for a germline mutation is family history for
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aHUS, whereas diagnosis at age ≤40 years or relapsing HUS
do not reach statistical significance.
Members of the Study group for Genetics of
Hemolytic Uremic Syndrome are:
From Germany: D Alscher, Stuttgart; M Anlauf, Bremer-
haven; S Arendt, Ansbach; W Arns u. Schnitzler, Ko¨ln; J
Bartel, Herne; P Bechstein, Hanau; R Beetz, Mainz; B
Oldenburg, Aurich; H Blume, Moers; N Bockreiss, Ober-
schleißheim; KP Bo¨hmer, Nu¨rnberg; E Braasch, Eberswalde;
KA Brensing, Bonn; D Bru¨ckner, Dortmund; K Budde,
Berlin; T Busch, Moers; CA Debusmann, Bottrop; W
Deininger, Weiden; K Dittrich, Erlangen; H Ehrich, Kitzin-
gen; C Erley, Tu¨bingen; W Fassbinder, Fulda; H Fehren-
bach, Memmingen; J Floege, Aachen; U Frei, Berlin; V
Gla¨ser, Plauen; D Glo¨er, Reinbek; B Gmelin, Nu¨rnberg;
S Gouw, Korbach; M Griebel, Mu¨nchen; J Groll, Berlin; R
Habersetzer, Emmering; K Ha¨llfritzsch, Unterhaching; HG
Hartmann, Saarbru¨cken; U Hoffmann/Wita, Hamm; P
Ho¨gner, Essen; M Kentsch, Itzehoe; M Ketteler, Aachen; G
Klaus, Marburg; V Kleint, Celle; K Klimas-Mu¨ller, Neuwied;
M Ko¨ber, Waiblingen; M Koepke, Ko¨ln; S Ko¨pf, Heidel-
berg; J Kothmann, Bayreuth; M Koziolek, Goettingen; B
Kra¨mer, Regensburg; I Krenz, Hamburg; B Krumme, Wies-
baden; M Kube, Bielefeld; U Kuhlmann, Stuttgart; K Ku¨hn,
Karlsruhe; C Lehne, Mu¨nster; R Lerch, Alto¨tting; P Loren-
zen, Flensburg; S Markau, Hall; J Materna, Backnang; H
Messner, Wuppertal; H Militzer, Hof; Mu¨ller, Dresden; W
Nettekoven, Bonn; A Nippe, Ansbach; K No¨hring,Waren; D
Oehmer, Gotha; G Offermann, Berlin; G Ohrisch, Roding;
Richter, Neuwied; B Riedl, Bayreuth; W Ries, Flensburg;
M Ries, Memmingen; H G Roeder, Karlsruhe; C Ro¨ger,
Ko¨ln; J Scha¨ffer, Peine; ANebel, Ko¨ln; G Scha¨tzle, Mu¨nchen;
M Schneider, Nu¨rnberg; B Schneider, Geilenkirchen; P
Schnu¨lle, Mannheim; M Scho¨mig, Heidelberg; C Scho¨nfeld,
Harburg; S Skelin, Heidelberg; J Sohn, Hameln; M Sohn,
Chemnitz; B Spohn, Gu¨nzburg; O Stenger, Hamburg; T
Stiegler, Offenbach; F Sto¨ckl, Darmstadt; T Strack,Mu¨nchen;
L Tegtmeier, Bremen; J To¨nnis, Kassel; B Ueberscha¨r, Mainz;
R Unbehaun, Gera; A von Zitzewitz, Ahrensburg; C Wan-
ner, Wu¨rzburg; M Weber, Ko¨ln; R Weitzell, Uelzen; G
Wichmann, Dresden; J Wiemer, Mu¨nchen; A Wiemeyer,
Dortmund; A Yavari, Grevenbroich; M Zahn, Plauen; W
Zimmermann, Gelsenkirchen.
From Austria: I Ettinger, Kirchdorf; A Ko¨nigsrainer, Inns-
bruck; T Mu¨ller, Wien; U Neyer, Feldkirch; A Pollak, Wien.
From Switzerland: U Widmer, Zu¨rich.
From Italy: P Riegler, Bozen.
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